August 26, 2020
Removal of restrictions on state purchases of foreign drugs for the treatment of leukemia and lymphoma in Russia
From August 8, 2020, to December 31, 2021, foreign medicines for the treatment of leukemia and lymphoma will be admitted to public procurement without restrictions. The Russian Prime Minister signed this resolution.

Foreign medicines included in the List of vital and essential medicines do not participate in auctions if there are similar offers from at least two manufacturers from the countries of the Eurasian Economic Union.

In some cases, such a limitation interferes with effective treatment, and changing the drug or using drugs from another manufacturer may worsen the patient's condition. This is especially true for rapidly progressive diseases that require stable therapy.

The following drugs will be admitted to public procurement without restrictions:

  • filgrastim,
  • caspofungin,
  • micafungin,
  • carboplatin,
  • voriconazole,
  • sevoflurane,
  • rituximab,
  • fludarabine.

The drugs are used in malignant neoplasms of lymphoid and hematopoietic tissues, as well as in the treatment of orphan diseases in children.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)